MX2016006758A - Composiciones y metodos de vectores para inducir una respuesta inmunitaria mediante el uso de vectores de poxvirus. - Google Patents
Composiciones y metodos de vectores para inducir una respuesta inmunitaria mediante el uso de vectores de poxvirus.Info
- Publication number
- MX2016006758A MX2016006758A MX2016006758A MX2016006758A MX2016006758A MX 2016006758 A MX2016006758 A MX 2016006758A MX 2016006758 A MX2016006758 A MX 2016006758A MX 2016006758 A MX2016006758 A MX 2016006758A MX 2016006758 A MX2016006758 A MX 2016006758A
- Authority
- MX
- Mexico
- Prior art keywords
- vectors
- recombinant poxviruses
- nucleic acids
- methods
- heterologous
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title 2
- 230000028993 immune response Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 230000005934 immune activation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan en la presente poxvirus recombinantes que comprenden ácidos nucleicos heterólogos o ácidos nucleicos naturales que especifican el exceso de ARN de cadena doble (ARNcd) en las etapas iniciales de la infección, que pueden comprender adicionalmente ácidos nucleicos heterólogos que codifican una o más moléculas coestimuladoras y/o ácidos nucleicos heterólogos que codifican uno o más antígenos asociados a una enfermedad o antígenos asociados al tumor, así como también las composiciones farmacéuticas que comprenden los poxvirus recombinantes y métodos y usos de estos. Los poxivirus recombinantes proporcionados en la presente mejoran la activación inmunitaria innata y adaptativa en sujetos comparados con poxvirus recombinantes idénticos que no tienen unidades de transcripción heterólogas o naturales que especifican un exceso de ARNcd en etapas iniciales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13005541 | 2013-11-28 | ||
| PCT/EP2014/075522 WO2015078856A1 (en) | 2013-11-28 | 2014-11-25 | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006758A true MX2016006758A (es) | 2016-09-06 |
Family
ID=49680779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006758A MX2016006758A (es) | 2013-11-28 | 2014-11-25 | Composiciones y metodos de vectores para inducir una respuesta inmunitaria mediante el uso de vectores de poxvirus. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20160376596A1 (es) |
| EP (2) | EP3074517B1 (es) |
| JP (2) | JP6641276B2 (es) |
| KR (1) | KR102504316B1 (es) |
| CN (1) | CN105829537B (es) |
| AU (3) | AU2014356546A1 (es) |
| BR (1) | BR112016011866A2 (es) |
| CA (1) | CA2929600A1 (es) |
| CY (1) | CY1124707T1 (es) |
| DK (1) | DK3074517T3 (es) |
| EA (1) | EA039037B1 (es) |
| ES (1) | ES2895977T3 (es) |
| HU (1) | HUE056105T2 (es) |
| IL (1) | IL245509B (es) |
| LT (1) | LT3074517T (es) |
| MX (1) | MX2016006758A (es) |
| MY (1) | MY188100A (es) |
| NZ (2) | NZ719934A (es) |
| PT (1) | PT3074517T (es) |
| SI (1) | SI3074517T1 (es) |
| UA (1) | UA127337C2 (es) |
| WO (1) | WO2015078856A1 (es) |
| ZA (1) | ZA201603187B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3073310A1 (en) * | 2017-08-24 | 2019-02-28 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody |
| SG11202100305SA (en) * | 2018-07-13 | 2021-02-25 | Univ Arizona State | Methods of treating cancer with tnf expressing myxoma virus |
| BR112021013507A2 (pt) | 2019-01-10 | 2021-11-16 | Janssen Biotech Inc | Neoantígenos da próstata e seus usos |
| JP2022546539A (ja) | 2019-09-02 | 2022-11-04 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | 粘液腫ウイルスを用いて癌を治療するための新しい腫瘍崩壊ウイルスプラットフォーム |
| BR112022009598A2 (pt) | 2019-11-18 | 2022-08-16 | Janssen Biotech Inc | Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos |
| WO2022241198A2 (en) * | 2021-05-13 | 2022-11-17 | Thomas Jefferson University | Use of ectromelia virus for cancer immunotherapy and vaccines |
| CN115043948B (zh) * | 2022-06-24 | 2024-05-28 | 青岛硕景生物科技有限公司 | 一种猴痘病毒特异性融合蛋白抗原及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5519239A (en) * | 1978-07-28 | 1980-02-09 | Green Cross Corp:The | Interferon-producing attractant |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| ATE420171T1 (de) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| EP1137792B9 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| ES2300261T3 (es) * | 1999-04-08 | 2008-06-16 | Novartis Vaccines And Diagnostics, Inc. | Potenciacion de la respuesta inmune para aplicaciones de vacunas y terapia genetica. |
| WO2000063364A2 (en) * | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
| AU2002231639B2 (en) | 2000-11-23 | 2007-01-04 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| CA2466413C (en) | 2001-12-04 | 2014-11-04 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| AU2003249059A1 (en) * | 2002-07-24 | 2004-02-09 | Arizona Board Of Regents | Use of vaccinia virus deleted for the e3l gene as a vaccine vector |
| US20050281782A1 (en) * | 2004-06-21 | 2005-12-22 | Howard Kaufman | Novel recombinant poxvirus composition and uses thereof |
| US7998733B2 (en) * | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
| DE602005027747D1 (de) * | 2004-12-22 | 2011-06-09 | Alnylam Pharmaceuticals Inc | Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen |
| EP2042604A1 (en) * | 2007-09-26 | 2009-04-01 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | VV promoter driven overexpression of recombinant antigens |
| JP5783642B2 (ja) | 2010-01-28 | 2015-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | Ｍｖａの主なゲノム欠失を含むワクシニアウイルス変異体 |
-
2014
- 2014-11-25 DK DK14806215.1T patent/DK3074517T3/da active
- 2014-11-25 MX MX2016006758A patent/MX2016006758A/es active IP Right Grant
- 2014-11-25 CN CN201480062145.2A patent/CN105829537B/zh active Active
- 2014-11-25 EP EP14806215.1A patent/EP3074517B1/en active Active
- 2014-11-25 BR BR112016011866A patent/BR112016011866A2/pt not_active Application Discontinuation
- 2014-11-25 EP EP21190638.3A patent/EP3971298A3/en active Pending
- 2014-11-25 PT PT148062151T patent/PT3074517T/pt unknown
- 2014-11-25 NZ NZ719934A patent/NZ719934A/en unknown
- 2014-11-25 AU AU2014356546A patent/AU2014356546A1/en not_active Abandoned
- 2014-11-25 NZ NZ759538A patent/NZ759538A/en unknown
- 2014-11-25 JP JP2016534624A patent/JP6641276B2/ja active Active
- 2014-11-25 LT LTEPPCT/EP2014/075522T patent/LT3074517T/lt unknown
- 2014-11-25 KR KR1020167013453A patent/KR102504316B1/ko active IP Right Grant
- 2014-11-25 ES ES14806215T patent/ES2895977T3/es active Active
- 2014-11-25 US US15/039,777 patent/US20160376596A1/en not_active Abandoned
- 2014-11-25 WO PCT/EP2014/075522 patent/WO2015078856A1/en active Application Filing
- 2014-11-25 SI SI201431894T patent/SI3074517T1/sl unknown
- 2014-11-25 UA UAA201606912A patent/UA127337C2/uk unknown
- 2014-11-25 HU HUE14806215A patent/HUE056105T2/hu unknown
- 2014-11-25 EA EA201691120A patent/EA039037B1/ru unknown
- 2014-11-25 MY MYPI2016701914A patent/MY188100A/en unknown
- 2014-11-25 CA CA2929600A patent/CA2929600A1/en active Pending
-
2016
- 2016-05-05 IL IL245509A patent/IL245509B/en active IP Right Grant
- 2016-05-11 ZA ZA2016/03187A patent/ZA201603187B/en unknown
-
2019
- 2019-12-26 JP JP2019235645A patent/JP7050044B2/ja active Active
-
2020
- 2020-04-11 US US16/846,325 patent/US20200325477A1/en active Pending
-
2021
- 2021-02-15 AU AU2021200985A patent/AU2021200985B2/en active Active
- 2021-11-08 CY CY20211100963T patent/CY1124707T1/el unknown
-
2024
- 2024-04-30 AU AU2024202790A patent/AU2024202790A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201603187B (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
| MX2018001213A (es) | Nuevos metodos para inducir una respuesta inmunitaria. | |
| PH12018500855A1 (en) | Herpes simplex virus vaccine | |
| TWI799368B (zh) | 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途 | |
| CY1124806T1 (el) | Αντισωματα enanti-cd40 και χρησεις αυτων | |
| MX352974B (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
| PE20181529A1 (es) | Vacunas de acido nucleico para el virus varicela-zoster (vzv) | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| TR201908550T4 (tr) | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. | |
| MX2018002106A (es) | Vacunas terapeuticas contra el hpv18. | |
| MX2019008303A (es) | Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika. | |
| EP3012322A4 (en) | GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF | |
| PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
| EA201891460A1 (ru) | Композиция дендритных клеток | |
| MY181175A (en) | Therapeutic hpv16 vaccines | |
| WO2015052543A3 (en) | Malaria vaccination | |
| MX343830B (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
| MX2017008096A (es) | Pestivirus. | |
| IL265942A (en) | A nucleotide sequence expressing an exosome anchor protein for use as a component | |
| WO2014151834A3 (en) | Methods and compositions relating to anti-ccr7 antigen binding proteins | |
| EA201792512A1 (ru) | Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник | |
| MX2017008087A (es) | Virus de la viruela porcina recombinante y vacunas. | |
| EP4226937A3 (en) | Non-neuroinvasive viruses and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |